Care of infants and children with SCD
To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.
Starts On:
7/1/2019: 12:00 AM
Ends On:
1/9/2020: 12:00 AM
Session Type:
Internet Activity Enduring Material
Credits:
1
Description:
Monica L. Hulbert, MD
Assistant Professor, Pediatrics
Division of Hematology and Oncology
Director, Pediatric Sickle Cell Disease Program
Disclosures: Dr. Hulbert's Spouse holds employment at Pfizer, Inc.
Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Sickle Cell Disease, September 15, 2017, which was supported in part by Novartis and Jazz Pharmaceuticals.
Regina Abel, PhD, Instructor in Occupational Therapy and Medicine
Disclosures: No financial relationships to disclose.
Morey Blinder, MD, Course Chair
Disclosures: Dr. Blinder is on the Speakers' Bureau for Novartis, Amgen, CSL Behring, and Janssen
Lauren Colquitt, BSN, RN, Clinical Nurse Coordinator, Division of Hematology
Disclosures: No financial relationships to disclose.
Allison King, MD, MPH, PhD, Course Chair
Disclosures: Dr. King has ownership/investment in Magenta
Christin Simpson, MSN, FNP-C, Inpatient Nurse Practitioner, Division of Hematology
Disclosures: No financial relationships to disclose.
Taniya Varughese, MSOT, OTR/L, Coordinator Occupational Therapy Support Program in Occupational Therapy
Disclosures: No financial relationships to disclose.
Abigail Yancey, PharmD, FCCP, BCPS, Professor of Pharmacy Practice, St. Louis College of Pharmacy
Disclosures: No financial relationships to disclose.
Faculty
Monica L. Hulbert, MD
Assistant Professor, Pediatrics
Division of Hematology and Oncology
Director, Pediatric Sickle Cell Disease Program
Disclosures: Dr. Hulbert's Spouse holds employment at Pfizer, Inc.
Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Sickle Cell Disease, September 15, 2017, which was supported in part by Novartis and Jazz Pharmaceuticals.
Planning Committee
Regina Abel, PhD, Instructor in Occupational Therapy and Medicine
Disclosures: No financial relationships to disclose.
Morey Blinder, MD, Course Chair
Disclosures: Dr. Blinder is on the Speakers' Bureau for Novartis, Amgen, CSL Behring, and Janssen
Lauren Colquitt, BSN, RN, Clinical Nurse Coordinator, Division of Hematology
Disclosures: No financial relationships to disclose.
Allison King, MD, MPH, PhD, Course Chair
Disclosures: Dr. King has ownership/investment in Magenta
Christin Simpson, MSN, FNP-C, Inpatient Nurse Practitioner, Division of Hematology
Disclosures: No financial relationships to disclose.
Taniya Varughese, MSOT, OTR/L, Coordinator Occupational Therapy Support Program in Occupational Therapy
Disclosures: No financial relationships to disclose.
Abigail Yancey, PharmD, FCCP, BCPS, Professor of Pharmacy Practice, St. Louis College of Pharmacy
Disclosures: No financial relationships to disclose.
Objectives:
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Discuss preventive care for newborns and children with sickle cell disease
- Review common complications of SCD in early childhood
- Discuss disease severity prediction in children with SCD
Additional Information:
Target Audience: This course is designed for intended for provide hematologists, primary care physicians, healthcare staff, pharmacists, and occupational therapists.
Date
Publication Date: July 1, 2019
Expiration Date: January 9, 2020
Target Audience: This course is designed for intended for provide hematologists, primary care physicians, healthcare staff, pharmacists, and occupational therapists.
Date
Publication Date: July 1, 2019
Expiration Date: January 9, 2020
Accreditation Information:
In support of improving patient care, this activity has been planned and implemented by Heartland Sickle Cell Disease Network and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Awarded for this Activity:
In support of improving patient care, this activity has been planned and implemented by Heartland Sickle Cell Disease Network and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Awarded for this Activity:
Credit Statement:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
References:
- Dallas Newborn Cohort, Quinn, Blood. 2010 Apr 29; 115(17): 3447–3452
- SCATE trial, Hankins 2014. Am J Hematol. 2015 Dec;90(12):1099-105
- CSSCD infant cohort, Meier, 2014. Am J Hematol. 2014 Sep;89(9):904-6
Disclosure Information:
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.
Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
